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Abstract
Cell death is essential for a plethora of physiological processes, and its deregulation characterizes
numerous human diseases. Thus, the in-depth investigation of cell death and its mechanisms
constitutes a formidable challenge for fundamental and applied biomedical research, and has
tremendous implications for the development of novel therapeutic strategies. It is, therefore, of utmost
importance to standardize the experimental procedures that identify dying and dead cells in cell
cultures and/or in tissues, from model organisms and/or humans, in healthy and/or pathological
scenarios. Thus far, dozens of methods have been proposed to quantify cell death-related parameters.
However, no guidelines exist regarding their use and interpretation, and nobody has thoroughly
annotated the experimental settings for which each of these techniques is most appropriate. Here, we
provide a nonexhaustive comparison of methods to detect cell death with apoptotic or nonapoptotic
morphologies, their advantages and pitfalls. These guidelines are intended for investigators who
study cell death, as well as for reviewers who need to constructively critique scientific reports that
deal with cellular demise. Given the difficulties in determining the exact number of cells that have
passed the point-of-no-return of the signaling cascades leading to cell death, we emphasize the
importance of performing multiple, methodologically unrelated assays to quantify dying and dead
cells.
Keywords
apoptosis; caspases; cytofluorometry; immunofluorescence; microscopy; mitotic catastrophe;
necrosis
In multicellular organisms, the timely execution of programmed cell death is critical for
numerous physiological processes including embryogenesis, post-embryonic development and
adult tissue homeostasis. It is, therefore, not surprising that deregulated cell death is a common
feature of a wide array of human diseases. On one hand, the unwarranted death of postmitotic
cells constitutes one of the most important etiological determinants of acute and chronic
pathologies including (but not limited to) ischemic, toxic, neurodegenerative and infectious
syndromes. Conversely, disabled cell death is frequently associated with hyperproliferative
conditions such as autoimmune diseases and cancer. Several well-established and experimental
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therapies target the molecular mechanisms of cell death, either to prevent the demise of cells
that cannot be replaced, or to facilitate the elimination of supernumerary and/or ectopic cells.
1 Thus, the precise characterization of the molecular machinery of cell death constitutes a major
challenge for present and future research, which has already and will continue to have
tremendous repercussions on the development of novel therapeutic approaches.
The first and most important question that any researcher who studies cellular demise needs
to answer is: when is a cell ‘dead’? Recently, the Nomenclature Committee on Cell Death
(NCCD) has formulated several recommendations on the use of cell death-related terminology.
2 Dying cells are engaged in a cascade of molecular events that is reversible until a first
irreversible process takes place, and the ‘point-of-no-return’ that delimits the frontier between
a cell’s life and death has been trespassed. So far, a single molecular event that accounts for
the point-of-no-return in the signaling cascades leading to cell death remains to be identified.
Thus, the NCCD has proposed that a cell should be regarded as ‘dead’ when (1) the cell has
lost the integrity of its plasma membrane and/ or (2) the cell, including its nucleus, has
undergone complete disintegration, and/or (3) its corpse (or its fragments) has been engulfed
by a neighboring cell in vivo.
In this context, another important issue is represented by the indisputable existence of numerous
cell death modalities.2 Cell death represents a highly heterogeneous process that can follow
the activation of distinct (although sometimes partially overlapping) biochemical cascades and
can manifest with different morphological features. For instance, cells can die as they display
an apoptotic morphology (which among other features is characterized by chromatin
condensation, nuclear fragmentation and overall shrinkage of the cell) or a necrotic one (which
is associated with a gain in cell volume, organellar swelling and disorganized dismantling of
intracellular contents). Mixed cell death morphotypes characterized by both apoptotic and
necrotic traits have also been described, which has led some investigators to suggest the
existence of a ‘continuum’ of cell death phenotypes, at least in specific experimental settings.
3 Such morphological heterogeneity frequently derives from the activation of separate
executioner mechanisms. Thus, beyond merely encyclopedic intents, the correct classification
of cell death into specific subroutines may be extremely important for its therapeutic
implications. As an example, tumor cells are often resistant to chemotherapeutic regimens that
induce apoptosis, but not to necrotic triggers. In this context, the induction of one specific cell
death mode (i.e., necrosis), as opposed to another (i.e., apoptosis), would result in an obvious
therapeutic advantage.
The term ‘autophagic cell death’ has been widely employed to indicate a type of cell death that
is accompanied by massive vacuolization of the cytoplasm.2 However, the relationship
between autophagy and cell death remains controversial.4,5 Multiple Drosophila
melanogaster developmental scenarios (including involution of salivary glands, early
oogenesis and removal of the extraembryonic tissue known as amnioserosa) provide in vivo
evidence that cell death can be (at least partially) executed through autophagy.6–9 Consistent
with these results, the knockout/knockdown of essential autophagy (atg) genes has been shown
to protect cultured mammalian cells from some lethal inducers, at least in specific experimental
settings.10 Still, more frequently, pharmacological and/or genetic inhibition of autophagy does
not prevent cell death, and rather accelerates it.11,12 This suggests that although cell death can
occur together with autophagy, the latter likely represents a prosurvival mechanism activated
by dying cells in the attempt to cope with stress.11,12 As very detailed guidelines concerning
the use and interpretation of assays for monitoring autophagy have been recently provided by
Klionsky and colleagues,13 this topic will not be discussed further in the present review.
Nowadays, dozens (if not hundreds) of methods are available for the detection of cell death-
related parameters in vitro (in cell cultures), ex vivo (in explanted tissues and/or organs) and
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in vivo (in model organisms and/or humans; Figure 1). Since the beginning of cell death
research, this methodological collection has been evolving, driven by the technological
innovation that has characterized the last decades. However, some of the classical methods to
identify dead and dying cells (e.g., light microscopy-based techniques) continue to be largely
employed by researchers (due to their simplicity and/or low cost), even though they may be
rather nonspecific and, therefore, inappropriate in the majority of experimental settings.
Conversely, the precise quantification of a single molecular process may be excessively
specific, and also result in the over- and/or underestimation of cell death. Numerous methods
to detect cell death can only be applied to a limited number of experimental settings, due to
intrinsic features of the model system or technical limitations of the platform on which such
protocols are implemented.
Beyond obvious technical variations, the experimental procedures to identify dead and dying
cells differ from one another with regard to (and hence may be classified according to) (1)
specificity (i.e., some techniques selectively detect apoptosis-related phenomena, such as
internucleosomal DNA cleavage, whereas others cannot discriminate between apoptotic and
nonapoptotic cell death subroutines); (2) sensitivity (which is determined by the lower
detection limit); (3) detection range (which relates to the upper detection limit); (4) precision
(i.e., cell death-related parameters can be detected in a qualitative, semiquantitative or
quantitative fashion); (5) throughput (which can be low, as for electron microscopy-based
methods, standard, as for normal laboratory practices, or high, as for automated procedures);
(6) cell death stage (meaning that biochemical processes belonging either to the induction/
initiation, integration/decision or execution/degradation phases of the cell death cascade can
be specifically quantified); (7) cell death parameter (i.e., morphological versus biochemical)
or (8) readout (which can be an end-point or a real-time measurement). Concerning specificity,
a clear-cut distinction has to be made between ‘general’ and ‘cell death-type specific’
techniques. Although the former (e.g., vital dyes) can detect end-stage cell death irrespective
of its type (most frequently by assessing the structural dismantling of dead cells and in particular
plasma membrane breakdown), the latter (e.g., caspase activation assays) monitor processes
that have been specifically, yet not exclusively, associated with a particular subroutine of cell
death. This hierarchical subdivision reflects the correct experimental approach that should be
used when studying cell death (see also ‘Concluding remarks’).
Irrespective of the possible categorization of the methods to detect cell death, standardized
guidelines on their use and interpretation have never been formulated. Recently, Klionsky and
colleagues have approached a similar issue concerning the techniques to detect autophagy.13
Along the lines of this work, we propose here a comparison of the most common methodologies
to identify and quantify dead and dying cells, with particular emphasis on their relative
advantages/draw-backs and on their suitability for specific versus common experimental
scenarios.
Light Microscopy, Electron Microscopy and (Immuno)cyto(histo)chemistry
Visual inspection by light microscopy provides a rapid and inexpensive means to detect cell
death in a generalized and rather nonspecific fashion. This can be done on living samples (in
phase contrast mode, for instance, to monitor the conditions of cultured cells), or on fixation
and staining of cytospins and/or histological sections. The most common cyto(histo)chemical
protocols include Papanicolaou and Mayer’s hematoxylin/eosin (H&E) stains, both of which
allow the visualization of multiple intracellular structures, and in particular of the nuclei. Thus,
cells displaying morphological changes that normally are associated with cell death, such as
pyknotic nuclei, membrane blebbing or swollen cytoplasm can be visualized. Still, these
techniques are time consuming and operator dependent, and tend to underestimate the fraction
of dead/dying cells. This is due to the fact that cells in the early phases of lethal cascades usually
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fail to display gross morphological modifications, and hence remain undetected by these
approaches. Similarly, light microscopy-based techniques fail to recognize completely
disintegrated cells, whose fragments are too small to be seen. These sources of underestimation
can be partially overcome by video or time-lapse microscopy, allowing for the cumulative
scoring of cell death throughout the entire duration of experiments. Moreover, when the
fraction of dead cells is low (as it is often the case in vivo), it may be difficult for the operator
to perceive them within the normal tissue architecture (for instance in histological sections).
In this context, the use of vital dyes (i.e., dyes that selectively stain either live or dead cells),
such as trypan blue or crystal violet, is advantageous in that it limits underestimation, by
allowing the identification of dead cells that have not yet undergone significant structural
modifications. Although exclusion dyes (i.e., vital dyes that cannot enter or are actively
extruded by healthy cells, yet are taken up by cells with permeabilized plasma membranes)
provide a very simple means to estimate the amount of live (and hence dead) cells in counting
chambers, light microscopy-based techniques are inappropriate for high-throughput
applications. However, visual inspection by light microscopy can be useful to follow the
degenerative changes that are associated with the death of postmitotic cells over time (e.g.,
neurons, cardiomyocytes and myotubes). Indeed, as these cells do not replicate, they cannot
be studied by methods that require a large number of cells (e.g., cytofluorometry) nor by
techniques that are based on proliferation (e.g., clonogenic assays; see below).
(Immuno)cyto(histo)chemistry protocols coupled with light microscopy allow for the
quantification (in cytospins or histological sections) of cells characterized by some (but not
all) of the biochemical changes associated with cell death. This applies, for instance, to caspase
activation or PARP-1 proteolytic processing, and in general to all molecular processes that can
be detected by specific primary antibodies, including activation-dependent accumulation (e.g.,
p53), overexpression (e.g., Puma); cleavage (e.g., procas-pases; caspase substrates),
phosphorylation/dephosphorylation (e.g., p53, p38MAPK), conformational changes (e.g., Bax;
Bak) and other posttranslational modifications (e.g., acetylation, sumoylation). Secondary
antibodies coupled to horseradish peroxidase or to alkaline phosphatase can be revealed with
chromogenic substrates, and positive cells display a brownish-blackish color, which is readily
detectable, for instance over an H&E background. Less prone to underestimation than
biochemical stains (and hence more suitable for quantitative applications), (immuno)cyto
(histo)chemistry protocols are also advantageous because they allow for the detection of early
cell death-related events, such as the cleavage of initiator caspases. Still, these methods heavily
depend on the performance (background, specificity) of the primary antibody of choice, and
are limited to low levels of throughput.
One classical application of cyto(histo)chemistry is the detection of DNA fragmentation by
the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)
method.14 This technique is characterized by higher sensitivity than most other cyto(histo)
chemical approaches and has long been considered to be the gold standard to detect apoptosis
in situ. However, TUNEL false positivity may result from necrotic cell death (at least in some
cases), as well as from inappropriate processing of samples, which may occur – for example
– during sectioning.15 For these reasons, although in many cases (and in particular in some
disease models)16 TUNEL remains the only method for investigating apoptosis in situ,
whenever possible, researchers should include appropriate positive and negative controls and
should corroborate the results of TUNEL by at least one independent experimental approach.
Electron microscopy permits the visualization of fine ultrastructural modifications that
accompany cell death, including gaps in the plasma and/or in the mitochondrial outer
membrane,17 mitochondrial swelling18 and the first phases of chromatin condensation (which
only later become visible by light microscopy).19 Although electron microscopy can provide
an impressive amount of ultrastructural information, the visual inspection of electron
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microphotographs should always be complemented by a robust quantitative approach. Indeed,
as the analysis is conducted on a per-cell basis and only a fraction of cells within each sample
can be studied, this is critical for researchers to avoid focusing their investigation on rare (or
even artefactual) morphologies. Moreover, sample processing/staining for electron microscopy
is very laborious and requires trained personnel. Nevertheless, immunoelectron microscopy
procedures can provide very detailed insights into the molecular mechanisms of cell death. As
an example, the use of secondary antibodies coupled to gold particles of different sizes has
been successfully employed to precisely visualize the colocalization of Bax with Bid and
VDAC-1 in apoptotic human tumor cells.20 Thus, although electron microscopy cannot be used
for routine determinations, it is nearly irreplaceable for the ultrastructural analysis of some
processes linked to cell death.
Table 1 summarizes the advantages and pitfalls of light microscopy, electron microscopy and
(immuno)cyto(histo)-chemistry applied to cell death research.
(Immuno)fluorescence Microscopy and Immunoblotting
Nearly all (immuno)cyto(histo)chemical protocols can be transposed to fluorescence
microscopy approaches, with a number of significant advantages. First, fluorescence generally
(but not always, see below) ensures a higher signal-to-noise ratio than chromogenic techniques,
which improves sensitivity. Second, the detection method does not involve an enzymatic
reaction, whose efficacy may be perturbed by several variables including buffer composition,
pH and temperature. Third, secondary antibodies coupled to fluorochromes with distinct
absorption/emission spectra are compatible with sophisticated costaining protocols, which
permits the routine detection of three to four distinct cell death-related events at the same time.
Fourth, fluorescent dyes and fluorescent fusion proteins can be employed in combination with
immunological methods, further extending the parameters that can be monitored at the same
time. Finally, confocal (but not conventional) immunofluorescence microscopy enables 3D
reconstitution of samples, which may be useful for colocalization experiments (see below for
a note of caution).
The most common applications of (immuno)fluorescence microscopy for cell death research
include, but are not limited to (1) quantification of viable cells by the calcein retention
technique;21,22 (2) highly specific detection of apoptotic cells in live tissue and embryos (from
model organisms as diverse as D. melanogaster, Xenopus leavis, zebrafish and mice) with
acridine orange (AO);23–25 (3) identification of live, apoptotic and necrotic cells on acridine
orange/ethidium bromide (AO/EB) staining;26 (4) visualization of nuclear condensation with
Hoechst 33342 or 4′,6-diamidino-2-phenylindole (DAPI);27 (5) TUNEL, performed with
fluorochrome-coupled streptavidin to recognize biotinylated dUTP;28 (6) stable mitochondrial
staining (for colocalization experiments, see below) with fixable Δψm-sensitive dyes (e.g.,
chloromethyl-X-rosamine, CMXRos);29 (7) real-time monitoring of the Δψm in living cells
via nontoxic Δψm-sensitive fluorochromes (e.g., 5,5′, 6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolcarbocyanine iodide, JC-1; tetramethylrhodamine methyl ester,
TMRM);26,30 (8) quantification of cells characterized by massive caspase activation;19 (9)
detection of the so-called mitochondrial permeability transition (MPT) via the calcein
quenching method;31 (10) analysis of the mitochondrial relocalization of proapoptotic proteins
from the Bcl-2 family (e.g., Bax, Bid);32,33 (11) detection of the cytosolic spillage of lysosomal
proteins (e.g., cathepsin proteases),34,35 which is indicative of lysosomal membrane
permeabilization (LMP);36 (12) monitoring of the mitochondrio-cytosolic (or mitochondrio-
nuclear) translocation of mitochondrial intermembrane space (IMS) proteins (e.g., cytochrome
c (Cyt c), apoptosis-inducing factor (AIF)).37–39 Notably, relocalization studies can be
performed as end-point measurements by indirect immunofluorescence staining,40 and also in
real time by video or time-lapse microscopy of living cells that have been engineered to express
Galluzzi et al. Page 7
Cell Death Differ. Author manuscript; available in PMC 2010 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
constitutive, inducible or photoactivatable green fluorescent protein (GFP)-tagged proteins.
32,33,41–43
Until recently, visual quantification of cells characterized by one or more cell death-related
parameters was required to obtain quantitative data from (immuno)fluorescence microscopy-
based techniques, which represented one of their most relevant weaknesses. Fortunately, this
has begun to change with the progressive dissemination of high-throughput workstations that
allow for automated image acquisition from 96-well plates and software-assisted image
analysis. In some cell types, autofluorescence (which results in a very poor signal-to-noise
ratio) greatly restricts the usefulness of fluorescence-based (as opposed to chromogenic)
detection. Moreover, as compared to (immuno)cyto(histo)chemistry, (immuno)fluorescence
microscopy is intrinsically limited in that it does not allow for the simultaneous observation
of labeled and unlabeled structures. This might be particularly relevant for histological studies,
which often involve the visual inspection of overall tissue architecture. At least partially, this
drawback can be circumvented by the sequential acquisition (from the same field) of each
fluorescent signal as well as of the bright and/or dark field, followed by software-assisted image
reconstitution.
Finally, to avoid common misinterpretations of immunofluorescence microscopy-derived
results, it should always be remembered that (1) protein-to-protein colocalization does not
necessarily mean protein-to-protein physical/functional interaction; (2) colocalization assays
require confocal microscopes (which, as opposed to conventional microscopes) can acquire
images from distinct z planes); (3) due to physical constraints, the resolution of such
instruments along the z axis is significantly worse than along the x and y axes, and never lower
than 350nm and (4) to compensate for limited Z-resolution, 3D reconstruction software is
generally based on extrapolation algorithms. For all these reasons, confocal
immunofluorescence microscopy is appropriate to determine rather gross colocalizations (e.g.,
between a protein and a subcellular compartment), but cannot replace immunoelectron
microscopy for extremely precise spatial determinations, nor coimmunoprecipitation assays to
ascertain protein-to-protein physical interactions.
Immunoblotting (alone or combined with immunoprecipitation) has also been widely
employed for qualitative and/or semiquantitative analysis of cell death-related phenomena,
including (de)phosphorylation-dependent activation of cell death regulators (e.g., p53, Bcl-2),
44,45 conformational changes in proapoptotic Bcl-2 protein family members (e.g., Bax, Bak),
46,47 caspase activation (by employing either monoclonal antibodies specific for active
caspases or antisera that recognize both the processed and proenzymatic caspase form),47
cleavage of caspase substrates (e.g., cytokeratin 18, PARP-1)47,48 and translocation of IMS
proteins (e.g., Cyt c, AIF) to extramitochondrial compartments.49 In contrast to
immunofluorescence microscopy-based methods, immunoblotting allows the study of
subcellular fractions, and in particular the analysis of the release of IMS proteins from purified
mitochondria.39 Nonetheless, immunoblotting protocols are time consuming, unsuitable for
large-scale applications and provide reliable semiquantitative results only when primary
antibodies are employed at subsaturating concentrations. Moreover, although fluorescence-
based detection ensures enhanced sensitivity as compared to classical chemiluminescence, the
detection of small and/or weakly expressed proteins may be difficult to achieve and/or require
prolonged optimization. Finally, it should be kept in mind that although (immuno)fluorescence
microscopy-based quantifications are performed on a per-cell basis, semiquantitative
immunoblotting data represent whole cell populations, irrespective of any intrapopulation,
intercell heterogeneity. Thus, immunoblotting is not ideal for the analysis of heterogeneous
cell samples such as primary tissues or solid tumors.
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In Table 2, the benefits and disadvantages of (immuno)-fluorescence microscopy- and
immunoblotting-based methods to monitor cell death are illustrated.
Cytofluorometry and Luminometry
The most convenient technique to study cell death on a per-cell basis is cytofluorometry. To
this aim, dozens of protocols have been optimized, for instance based on (1) cell-permeant
probes with different functional properties (e.g., 3,3′dihexiloxalocarbocyanine iodide
(DiOC6(3)), JC-1 or TMRM, to measure Δψm; calcein, to monitor MPT);50,51 (2) plasma
membrane-impermeant fluorochromes, used as exclusion dyes (e.g., DAPI; propidium iodide
(PI));52 (3) fluorochrome-coupled secondary antibodies, for indirect immunostaining
procedures (which can detect nearly all processes that can be visualized by
immunofluorescence microscopy, see above); (4) chromatinophilic dyes, to quantify cells with
a sub-G1 DNA content (e.g., DAPI or PI, on plasma membrane permeabilization; Hoechst
33342);53 (5) fluorochrome-coupled Annexin V, to detect the exposure of phosphatidylserine
(PS) on the outer leaflet of the plasma membrane;54 (6) fluorogenic caspase or cathepsin
substrates 55,56 or (7) oxidative stress-sensitive probes (e.g., 2′,7′-dichlorodihydrofluorescein
diacetate (H2DCFDA), hydro-ethidine (HE)).40,57 Moreover, cytofluorometry has been
employed to detect the morphological modifications that characterize apoptosis (i.e., cell
shrinkage and augmented granularity of the intracellular content), the changes in morphology
and Δψm dissipation of purified mitochondria undergoing MPT in vitro,58,59 as well as a
readout for TUNEL.
The detection of light scattering and up to 10 different fluorescent signals allows for the
simultaneous yet independent analysis of 10–12 distinct parameters on living or fixed cell
suspensions. In this context, it is critical to remember that not all protocols for cytofluorometry
are compatible with each other, and hence can be combined into a single multiparametric study.
This relates to the possible overlap between emission spectra from distinct fluorochromes, and
also to sample processing. As an example, protocols that require plasma membrane
permeabilization (e.g., assessment of the cell cycle distribution with chromatinophilic
fluorochromes, quantification of intracellular antigens by indirect immunostaining) are
inherently incompatible with methods based on intact cells (e.g., incorporation of exclusion
dyes, Annexin V-mediated detection of PS exposure).
In contrast to (immuno)fluorescence microscopy-based methods, cytofluorometric techniques
provide quantitative results independently from visual quantification of ‘positive’ events,
which limits operator-dependent bias, and allows for the rapid acquisition of 10 000–100 000
events per sample, resulting in increased statistical power and higher throughput. The recent
introduction of 96-well plate cytofluorometers will further augment the applicability of these
approaches to high-throughput screening (HTS) procedures. Still, the need for a large number
of cells makes cytofluorometry inappropriate for the study of primary (and in particular
postmitotic) cell cultures. Moreover, as cytofluorometric methods require cell-to-cell
dissociation, they are intrinsically unsuitable for the direct study of histological sections.
Fluorogenic caspase substrates are prone to unspecific degradation, both in cells and in cell
lysates, which may lead to false-positive results. In this context, the use of caspase inhibitors
can help in determining the caspase-specific signal. Finally, as a caveat to the use of PS
exposure alone as a marker of early apoptosis, it should be noted that (1) if plasma membranes
are permeabilized (as during late apoptosis or early necrosis) Annexin V can bind to
intracellular PS; (2) PS exposure can prepare cells for phagocytic removal independently of
apoptosis60 and that (3) PS exposure can be compromised in cells in which autophagy is
impaired.61
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Luminometry has been primarily applied to cell death research for the quantification of
intracellular bioenergetic stores, based on reports suggesting that the ATP/ADP ratio can be
used to discriminate between apoptosis, necrosis and arrested proliferation.62 Luminometry-
based techniques are extremely sensitive (due to a nearly undetectable background) and 96-
well plate luminometers are widely available. However, ATP and ADP levels are rapidly
affected by extracellular and/or intracellular perturbations, and hence cannot be used alone
(without further validation by complementary tests) for the detection of a complex phenomenon
such as cell death. As an example, nutrient depletion often results in a significant consumption
of ATP that is not followed by cell death, due to the activation of the autophagic pathway.63
Table 3 summarizes the advantages and drawbacks of cytofluorometry and luminometry-based
methods for the study of cell death.
Spectrophotometry
Due to the fact that they are fairly suitable for automation (and hence adaptable to high-
throughput procedures), numerous 96-well plate-based methods are used to study cell death-
related parameters. For instance, plasma membrane breakdown (as a sign of cytotoxicity) can
be detected by assessing culture supernatants for the activity of enzymes that are normally
confined within the cell (e.g., lactate dehydrogenase (LDH)).47 Moreover, the activity of the
mitochondrial respiratory chain is widely considered as an indicator of the number of viable
cells, and hence measured to study cell death versus proliferation. To this aim, the most
common protocols involve membrane-permeant colorless tetrazolium salts, which can be
administered to living cells and are converted by metabolically active mitochondria into
colored products.19,47,64 The widely employed, first-generation tetrazolium derivative 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) is reduced by mitochondrial
dehydrogenases to formazan, which is water-insoluble and hence accumulates in cytosolic
crystals. As a consequence, the spectrophotometric quantification of formazan requires cell
lysis and overnight solubilization of crystals, which – however – are cytotoxic even in small
amounts. Thus, MTT conversion can only be employed in the context of endpoint
determinations. As opposed to MTT, second-generation tetrazolium derivatives (e.g., 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) or 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate
(WST-1)) are metabolized into nontoxic, water-soluble, membrane-permeant products, which
freely diffuse in the culture supernatant. Thus, MTS and WST-1 do not compromise the
viability of cultures, thereby being compatible with recurring and/or real-time determinations.
Both LDH release and MTT/MTS/WST-1 conversion are commonly employed for cell death
research, presumably because (1) they allow for the simultaneous analysis of a large number
of specimens; (2) they are rapid and do not require preprocessing of samples (e.g., cell lysis);
(3) they do not need specialized laboratory equipment; (4) ready-made kits are available, which
often include appropriate controls and (5) they are fairly economical (as compared to
immunological techniques). Nevertheless, both LDH release and MTT/MTS/WST-1 tests
suffer from considerable drawbacks. For instance, the release of LDH cannot be used for
discriminating among distinct cell death modalities. Moreover, this test measures an enzymatic
activity, which tends to decrease with time as a result of natural degradation, and can be affected
by several variables, including pH as well as the presence of specific components in the culture
medium. The conversion of MTT/MTS/WST-1 by mitochondrial enzymes may reflect
metabolic alterations that do not necessarily correlate with the number of viable cells. Medium
overconsumption and/or excessive cell density are two very common situations that result in
a pronounced shutdown of mitochondrial functions. In these conditions, the use of an MTT/
MTS/WST-1-based test alone would lead to the underestimation of the number of living cells.
In summary, the use of these colorimetric methods is advisable only for the preliminary phase
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of a cell death study, when hundreds to thousands of conditions have to be screened, and only
as long as relevant controls are included. In this context, a valuable approach would be to
integrate these assays with one another, allowing for the cross-confirmation of the cytotoxicity
and proliferation datasets.
Several kits based on the enzyme-linked immunosorbent assay (ELISA) principle are available
to measure cell death-related parameters in cell culture supernatants, intact cells, subcellular
fractions, tissue extracts or body fluids. ELISA-based assessments have been optimized to
monitor phenomena as different as Cyt c release, caspase-3 activation, release of intracellular
proteins following plasma membrane breakdown, presence of dissociated nucleosomes due to
chromatin fragmentation, and expression on the cell surface of death receptors and/or their
ligands, for instance. Nearly all these methods can be implemented on 96-well plates, allowing
for quantification by standard laboratory spectrophotometers, and they are often characterized
by increased sensitivity. Depending on the specific process that is monitored, some of these
protocols may require laborious preprocessing of samples, which in turn limits throughput. As
an example, ELISA-based kits that quantify Cyt c release require subcellular fractionation, and
hence provide few/no advantages as compared to immunofluorescence microscopy or
cytofluorometry.27 Still, miniaturized assays of this kind are well adapted for the precise
quantification of cell death-related factors released in the culture medium or in body fluids by
dead/dying cells (e.g., nuclear matrix protein (NMP)),65 which usually requires no/limited
preprocessing. In this context, two interesting applications are represented by the detection of
cytoplasmic versus extracellular histone-associated DNA fragments,66 and of caspase-cleaved
versus full-length cytokeratin 18 in extracellular fluids,67,68 because they can provide an
estimation of apoptotic versus nonapoptotic cell death. For the correct interpretation of this
kind of quantitative data – however – it should be noted that all ELISA-detectable markers
decay (perhaps with the exception of caspase-cleaved cytokeratin 18), due to both enzymatic
and nonenzymatic reactions. This precludes any quantitative correlation between the
concentration of a given marker and the percentage of dead/dying cells, which in turn makes
these assays not ideal for cell death research.
Spectrophotometry has often been used to monitor MPT in vitro, on mitochondria purified
from cell cultures or rodent organs and resuspended in sucrose media. Under these conditions,
MPT leads to an abrupt increase in the volume of the mitochondrial matrix (known as ‘large
amplitude swelling’), which can be followed by measuring the absorbance of the mitochondrial
suspension at 545 nm. This method has been successfully implemented on 96-well plates,
which can be monitored by standard laboratory spectrophotometers.27 As most of these
instruments are able to simultaneously measure several types of signal (e.g., absorbance,
fluorescence, luminescence), swelling measurements can be combined with additional tests
(e.g., calcein quenching assays, Δψm-sensitive dyes, Ca2+-sensitive probes) in the context of
a multiparametric analysis.69,70 Moreover, the use of pure mitochondrial suspensions enables
investigators to define a specific experimental microenvironment, and hence is essentially
irreplaceable for studying the direct induction of MPT by a given molecule in the absence of
metabolic interference. For the same reasons, this technique cannot be used to investigate the
effect of molecules that act on mitochondria by indirect mechanisms, for instance via metabolic
intermediates or by activating intracellular signaling pathways. Finally, large amplitude
swelling is not easily exploitable in high throughput applications for at least two reasons. First,
such applications would require a large amount of mitochondria, in turn demanding either the
killing/postmortem processing of dozens of rodents at the same time or the simultaneous culture
and subcellular fractionation of billions of cells. Second, in energized buffers in vitro,
mitochondria retain their structural and functional integrity only for a limited time (4–6 h).
In Table 4, spectrophotometric methods for monitoring cell death are compared based on their
advantages and pitfalls.
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Other Techniques
Clonogenic assays constitute a technique of choice to determine the long-term fate of
proliferating cells, because they can identify an irreversible arrest of cell growth occurring so
late that it would go undetected by other methods.71 Although clonogenic assays cannot
differentiate between cell demise and senescence (which is not a form of cell death),2 they
represent the gold standard method to study the cytotoxic versus cytostatic effects of anticancer
agents. The long-term fate of senescent cells has not yet been precisely determined, and may
considerably fluctuate in distinct experimental settings. Most likely, with time, senescent cells
activate a hitherto unidentified signaling cascade that eventually ensures their disposal.
However, as loss of clonogenicity does not necessarily derive from cell demise,2 clonogenic
assays are intrinsically not ideal to study ‘pure’ cell death.
DNA agarose gel electrophoresis followed by EB staining has represented a cornerstone
method to discriminate between apoptotic, internucleosomal DNA fragmentation (resulting in
the so-called ‘DNA ladder’, whose ‘rungs’ are represented by DNA fragments of 180 bp and
multiples thereof) and necrotic, nonspecific DNA degradation (resulting in a ‘smear’ of
randomly degraded DNA).72 Although less laborious than protein electrophoresis, this method
(as opposed to immunoblotting) is being increasingly disregarded due to the existence of cost-
effective alternatives that monitor the same process, such as TUNEL. In spite of the fact that
agarose gel electrophoresis is less prone to false positivity than TUNEL and that
noncarcinogenic nonradioactive stains provide a safe alternative to ethidium bromide,
nowadays this technique is rarely used in cell death research.
One recently developed technological platform, known as ImageStream, allows for the
simultaneous acquisition of both overall fluorescence and of several microphotographs (in
either bright-field, dark-field or fluorescence imaging mode) from each flowing cell. This
instrument, which combines the visual resolution of (immuno)fluorescence microscopy with
the statistical power of cytofluorometry, is being increasingly applied to cell death research.
As an example, unique combinations of photometric and morphometric measures, as acquired
by the ImageStream cytofluorometer in a single run, have been used to discriminate among
live, (early and late) apoptotic and necrotic cells.73 It can be anticipated that several other
techniques to quantify cell death-related parameters will be implemented on this technological
platform during the next few years.
Additional protocols to detect cell death-related parameters rely on nuclear magnetic resonance
(NMR), high-pressure liquid chromatography (HPLC) and mass spectrometry (MS). For
instance, the NMR properties of the structured water (i.e., bound to macromolecules) within
mitochondria have been exploited to discriminate among MOMP, MPT and more complex
scenarios (such as those affecting mitochondria in vivo).74 HPLC has been used to quantify
the release of Cyt c from purified rat liver mitochondria, which is more rapid and ensures higher
sensitivity than ELISA- or immunoblotting-based methods.75 Proteomic approaches based on
subcellular fractionation followed by MS analysis have been used in multiple cell death-related
settings, including the identification of proteins released by mitochondria undergoing MPT,
76 or of proteins that are exposed on the plasma membrane surface of apoptotic cells.77 These
techniques, and in particular MS-based proteomic studies, provide a large amount of
experimental data, which allows for the in-depth investigation of cell death-related phenomena.
However, they are suboptimal for routine determinations, because each requires a sophisticated
technology, qualified personnel and a nonnegligible phase of optimization for every
experimental protocol.
Table 5 presents the benefits and drawbacks of additional techniques applied to cell death
research.
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Concluding Remarks
Dozens of methods exist to measure cell death-related parameters, which depend on distinct
technologies and which can be distinguished with regard to their specificity, sensitivity,
detection range, precision and throughput. Each of these techniques was originally developed
for a specific purpose, and some have evolved toward more general applicability. Thus, a
cornucopia of protocols is available for the study of cell death. Nevertheless, none of these
methods is sufficient per se to unambiguously demonstrate cell death, and a combination of
complementary yet unrelated techniques should always be employed (see below). Such a
methodological profusion may result (and has indeed too often resulted) in the use of assays
that are completely inappropriate for the experimental setting under investigation. Both authors
and reviewers must be blamed for the publication of papers in which cytotoxic and/or
cytoprotective effects have been erroneously described, due to the use of inappropriate
methods. Thus, in multiple instances, caspase activation has been (mis)interpreted as an
unequivocal sign of apoptotic cell death when it is known that caspases also participate in many
processes not linked to cellular demise.78 This common mistake can now be avoided thanks
to the increasing knowledge on the specific substrates that are cleaved by caspases during cell
death but not in cell death-unrelated scenarios.79 As an example, in erythroblasts, the
transcription factor GATA-1 is cleaved by caspase-3 on death receptor engagement,80 yet it
remains uncleaved when caspase-3 is activated during erythroid differentiation.81
No guidelines will ever address in a specific fashion each experimental scenario related to
cellular demise. Thus, to avoid false-negative and/or -positive results as well as gross
misinterpretations, researchers should approach the study of cell death (as defined by the
etymological recommendations recently provided by the NCCD)2 by bearing in mind the
following two fundamental questions: (1) are cells truly dead, and if so, (2) by which subroutine
did cell death occur? To answer the first question, investigators need to combine at least two
distinct methods that assess end-stage cell death (e.g., LDH release and incorporation of
exclusion dyes, in vitro), and perform, whenever possible, long-term survival assays to detect
delayed cell death events (especially for postmitotic cells). In doing so, they will obtain a
reliable, quantitative evaluation of cell death, which is a sine qua non for subsequent studies
(see below).
Similarly, to characterize cell death in mechanistic terms (i.e., to answer the second question),
at least two complementary, but methodologically unrelated, techniques should be employed
to demonstrate the involvement of the same biochemical phenomenon. As an example, the
activation of caspases may be indisputably proved by combining miniaturized fluorogenic
assays with cytofluorometry- and/or immunofluorescence microscopy-based tests. As cell
death is highly heterogeneous – however – the signaling pathways that lead to cell death may
differ even across relatively similar experimental settings. Thus, it remains at each
investigator’s discretion to decide which are the most appropriate biochemical parameters that
should be monitored for the mechanistic characterization of cell death in his/her experimental
setup. As a final – but cardinal – note of caution, it should always be remembered that several
cell death-related phenomena (e.g., activation of caspases, p53-dependent gene transactivation)
also occur in cell death-unrelated settings (e.g., differentiation of several hematopoietic
precursors, DNA repair).78,82 It is, therefore, crucial for researchers to answer the above-
mentioned questions in the correct order, to avoid the arguably worst mistake of all:
investigating the mechanisms of cell death in the absence of cell death.
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LDH, lactate dehydrogenase
MOMP, mitochondrial outer membrane permeabilization
MPT, mitochondrial permeability transition
MS, mass spectrometry
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tetrazolium
MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
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TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling
WST-1, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate
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Figure 1.
Methods to detect cell death-related variables. Nowadays, a cornucopia of techniques is
available to monitor cell death-related parameters. Within this ‘methodological abundance/
redundancy’, the choice of the most appropriate techniques and the correct interpretation of
results are critical for the success of any study dealing with cell death. Here, the most common
procedures to detect dead/dying cells are indicated, together with the technical platforms that
are required for their execution and the types of specimens on which they can be applied. Please
see the main text for further details. Δψm, mitochondrial transmembrane potential; HPLC, high-
pressure liquid chromatography; MOMP, mitochondrial outer membrane permeabilization;
MPT, mitochondrial permeability transition; MS, mass spectrometry; NMR, nuclear magnetic
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resonance; PS, phosphatidylserine; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel
electrophoresis
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Table 1
Light microscopy, electron microscopy and (immuno)cyto(histo)chemistry applied to cell death research
Method Advantages Drawbacks Notes
Light microscopy
  IHC Quantitative detection of early cell
death-related events
Less prone to underestimation than
cytochemistry
Relies on the performance of the
primary antibody of choice
Detects only gross relocalizations
of IMS proteins to the nucleus
Limited throughput
Operator-dependent
Detection of biochemical
changes associated
with cell death (e.g.,
translocation of AIF or
EndoG to the nucleus,
activation of caspases, p53
phosphorylation)
  Cytochemistry Allows visualization of the overall
tissue architecture
Operator-dependent Detection of morphological
hallmarks of dying/
dead cells in histological
sections or cytospins
  •H&E stain (in histological sections) Prone to false negativity
  •PAP stain Inappropriate for quantitative
applications
  TUNEL Higher sensitivity than classic
IHC approaches
Prone to false-positive results, for
instance due to sample processing
Detection of free 3′-hydroxyl
ends in DNA
  Visual inspection On living samples Rapid and
inexpensive
Lacks specificity To monitor the general
conditions of cell
Rapid and inexpensive Highly prone to underestimation cultures
  Vital dyes Limit underestimation by
recognizing cells that have
Unable per se to distinguish
between apoptosis and necrosis
Exclusion dyes are extruded
by healthy cells,
  •Trypan blue not yet undergone relevant
structural modifications
Crystal violet stains all adherent
cells, irrespective of their
viability
yet are taken up by cells with
ruptured plasma
  •Crystal violet membrane
Electron microscopy
  SEM/TEM Detection of subtle changes in
organelle ultrastructure that
occur early in the cascade of events
leading to cell death
Inappropriate for large-scale
quantitative applications
May be poorly representative of
the general sample conditions
Laborious, time-consuming,
requires trained personnel
Analyzes morphological
hallmarks of apoptosis
at an ultrastructural level
  Immunoelectron
microscopy
Irreplaceable for an extremely
precise (co)localization of proteins
Expensive, time consuming,
unsuitable for quantification
Relies heavily on the primary
antibody of choice
Antibodies coupled to
electron-dense particles
of different sizes allow for
colocalization assays
Abbreviations: AIF, apoptosis-inducing factor; EndoG, endonuclease G; H&E, hematoxylin/eosin; IHC, (immuno)cyto(histo)chemistry; IMS,
mitochondrial intermembrane space; PAP, Papanicolau; SEM, scanning electron microscopy; TEM, transmission electron microscopy; TUNEL, terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling
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Table 2
(Immuno)fluorescence microscopy- and immunoblotting-based methods to detect cell death
Method Advantages Drawbacks Notes
(Immuno)fluorescence microscopy
  AO staining Allows for the highly specific
identification of apoptotic
cells
AO undergoes photobleaching
after several seconds
The elevated specificity of AO for
in live tissues and embryos
from various model
organisms
Stained tissues must be
observed and photographed
immediately
apoptotic cells within live tissues and
immediately embryos is still not fully understood
  AO/EB staining Very rapid and simple EB is carcinogenic AO stains both live and dead cells,
while
Allows for the discrimination
among live, (early and late)
Some expertise may be
required to clearly distinguish
EB is taken up only by cells that have
lost
apoptotic and necrotic cells between late apoptotic and
necrotic cells
plasma membrane integrity
  Calcein retention Simple technique Diluted calcein-AM must be
used immediately after
Cell-permeant, nonfluorescent calcein-
Suitable for both proliferating
and nonproliferating cells
preparation, as it
spontaneously hydrolyzes
AM is hydrolyzed by IC esterases to
Higher signal-to-noise ratio
than other fluorochromes
Calcein is actively extruded by
MDR1-overexpressing cells
calcein, which is fluorescent and
retained
by viable cells
  Calcein quenching Allows for the visualization of
mitochondria with an intact
IM
Reversible permeabilization
of the IM leads to the loss of
Detects the loss of barrier function of
the
Suitable for videomicroscopy calcein signal in the absence of
MPT
IM to ions (in particular to Co2+)
  Caspase activation assays Quantitative analysis on a per-
cell basis (as opposed to IB)
Operator dependent Based on antibodies that recognize
active
The cleavage of cell-
permeant, fluorogenic
substrates can
Caspase-activation may occur
in cell death-unrelated
caspases or cleaved substrates
be monitored in living cells settings Based on cell-permeant fluorogenic
Immunostainings heavily
depend on the performance of
primary antibodies
substrates
  Δψm-sensitive fluorochromes Allow for the visualization of
energized mitochondria
Δψm can be partially reduced
in cell death-unrelated
Cationic lipophilic probes accumulate
in
  •Fixable (e.g., CMXRos) No need for permeabilization settings, and this may be hard
to differentiate from
mitochondria driven by the Δψm
  •Nonfixable (e.g., JC-1, TMRM) Fixable probes may be useful
in colocalization experiments
irreversible loss Ratiometric dyes (e.g., JC-1) change
Nonfixable probes allow for
real-time monitoring of Δψm
Fixable probes are
mitochondrio-toxic and hence
suitable
emission spectra as a function of Δψm
only for end-point
determinations
  Nuclear counterstaining Labeling is rapid Hoechst 33342 and DAPI are
very sensitive to
Nuclear pyknosis is a classical hallmark
  •DAPI Useful to clearly identify
nuclei in colocalization
assays
photobleaching Inappropriate
on its own to conveniently
of apoptotic cells
  •Hoechst 33342 Hoechst 33342 is cell
permeant
monitor cell death
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Method Advantages Drawbacks Notes
  Relocalization No need for subcellular
fractionation (as opposed to
IB)
Require confocal microscopy MOMP is monitored by assessing the
  •IMS proteins (e.g., AIF, Cyt c) Indicative of the subcellular
localization of IMS proteins
At least two IMS proteins
should be evaluated, to
exclude
subcellular relocalization of IMS
proteins
  •Proapoptotic Bcl-2 proteins upon mitochondrial release artifacts The translocation and full insertion into
  (e.g., Bax, Bid) Fusion proteins allow for real-
time (video or time-lapse
Two-color colocalization
approaches are required (with
the OM of Bax mediates MOMP
  •Lysosomal proteins microscopy-based) studies sessile markers and/or
functional dyes specific for
other
LMP leads to the cytosolic spillage of
  (e.g., cathepsins) organelles) cathepsins, which are able to induce
Unsuitable for very precise
spatial determinations
MMP
  Posttranslational (in)activation Quantitative analysis on a per-
cell basis (as opposed to IB)
Operator dependent Analysis of structural changes in cell
  (e.g., Bax, p53) Detects early biochemical
events in cell death cascades
Specific conformations may
be unstable and get lost during
death regulators
permeabilization or fixation
TUNEL Useful in costaining
protocols, to confirm DNA
Prone to false-positive results,
for instance due to sample
Detection of free 3′-hydroxyl ends in
DNA
fragmentation processing
  Immunoblotting
  Caspase activation assays Applicable to subcellular
fractions (as opposed to IF or
Semiquantitative (the analysis
involves entire cell
Based on antibodies that recognize
active
cytofluorometry) populations) caspases, their cleaved substrates or
Based on standard laboratory
equipment
Small protein fragments (such
as degradation products)
both the inactive and active forms of
may be difficult to detect caspases
  Release of IMS proteins Allows for the study of
subcellular fractions and
purified
Time-consuming MOMP is monitored by assessing the
mitochondria (e.g., AIF, Cyt c) mitochondria (as opposed to
IF)
Not suitable for large-scale or
high-throughput applications
presence of IMS proteins in
May require a significant
amount of starting material
nonmitochondrial subcellular fractions
  Posttranslational (in)activation Allows the monitoring of
early biochemical events of
the cell
Relies on conformation- or
neoepitope-specific
antibodies
Analysis of structural changes in cell
(e.g., Bax, p53) death cascade Specific conformations may
be unstable and get lost during
death regulators
purification or electrophoresis
Abbreviations: AIF, apoptosis-inducing factor; AM, acetomethoxy; AO, acridine orange; CMXRos, chloromethyl-X-rosamine; Cyt c, cytochrome c;
Δψm, mitochondrial transmembrane potential; DAPI, 4′,6-diamidino-2-phenylindole; EB, ethidium bromide; IB, immunoblotting; IC, intracellular; IF,
(immuno)fluorescence microscopy; IM, mitochondrial inner membrane; IMS, mitochondrial intermembrane space; C-1, ′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolcarbocyanine iodide; LMP, lysosomal membrane permeabilization; OM, mitochondrial outer membrane; MDR1, multidrug
resistance protein 1; MOMP, mitochondrial outer membrane permeabilization; MPT, mitochondria permeability transition; TMRM, tetramethylrhodamine
methyl ester; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling
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Table 3
Cytofluorometric and luminometric techniques to monitor cell death-related variables
Method Advantages Drawbacks Notes
Cytofluorometry
  Annexin V assay Rapid, does not require fixation
Specific for an early event in the
executioner phase of apoptosis
Annexin V exists conjugated with
different fluorescent and
nonfluorescent labels
Annexin V fixes IC PS when
plasma membranes are
ruptured
PS exposure can take place
independently from
apoptosis
PS exposure may be impaired in
autophagy-deficient
cells
Annexin V binds to PS, which
in apoptotic
cells is exposed to the outer
leaflet of the
plasma membrane before
DNA
fragmentation and nuclear
breakdown
  Calcein quenching Allows the discrimination
between IM and OM
permeabilization
Cannot identify transient and
reversible IM that may
occur in cell death-unrelated
settings
Detects the loss of barrier
function of the
IM to ions (in particular to
Co2+)
  Caspase activation
assays
Quantitative (as compared to IB)
Allow for the analysis of large cell
populations (as opposed
to IF), on a per-cell basis (as
opposed to IB)
Caspase activation may occur in
cell death-unrelated
settings
Immunostraining requires cell
permeabilization and
fixation
Based on antibodies that
recognize active
caspases or cleaved substrates
Based on cell-permeant
fluorogenic
substrates
Fluorogenic substrates are prone
to unspecific degradation
  DNA content analysis Concomitant analysis of cell cycle
distribution and
Carcinogenic reagents Cell death is monitored by the
  •DAPI apoptosis A high number of events is
required for significance
quantification of events with
a sub-G1
  •Hoechst 33342 Hoechst 33342 does not require
permeabilization, can be
DAPI and PI require sample
permeabilization and
DNA content
  •PI used in triple stainings (but
requires UV excitation)
fixation
  Δψm-sensitive dyes Quantitative (as compared to IF) Δψm can be transiently lost in cell
death-unrelated
MMP is detected by
monitoring the
  •DiOC6(3) On living cells or upon fixation settings dissipation of the Δψm
  •CMXRos Several dyes exist with distinct
spectra, allowing for
costaining
Some fluorochromes exhibit
relevant self-quenching
  Posttranslational Quantitative (as compared to IB) Dependent on the performance of
conformation- or
Analysis of structural changes
in cell
  (in)activation Rapid analysis of large cell
populations (as opposed to IF)
neoepitope-specific antibodies death regulators (e.g., Bax,
p53)
  (e.g., Bax, p53) on a per-cell basis (as opposed to
IB)
Specific conformations may be
poorly stable and lost
at fixation
  ROS-sensitive Rapid, do not require cell
permeabilization
Temporary ROS overload not
always results in cell
ROS overgeneration is very
often a
  fluorochromes Allow for the estimation of
intracellular ROS levels
death prelude of MPT
    •H2DCFDA Probes specific for a single ROS
may show partial
    •HE cross-reactivity
  TUNEL Allows for long-term storage of
fixed samples
Useful in costaining protocols
TUNEL false positivity can
follow inappropriate
processing Expensive
Detection of free 3′-hydroxyl
ends in DNA
  Vital dyes Quantitative (as compared to light
microscopy-based
Unable per se to distinguish
between apoptotic and
Exclusion dyes are extruded
by healthy
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Method Advantages Drawbacks Notes
  •DAPI assays) necrotic cell death cells, yet are taken up by cells
with
  •PI Routinely employed in several
costaining protocols
ruptured plasma membrane
Luminometry
  Quantification of IC
ATP
Commercially available kits ATP/ADP levels may be affected
by numerous cell
ATP/ADP ratios are used to
differentiate
Miniaturized format death-unrelated phenomena between apoptosis and
necrosis
Standard laboratory equipment
Abbreviation: CMXRos, chloromethyl-X-rosamine; Δψm, mitochondrial transmembrane potential; DAPI, 4′,6-diamidino-2-phenylindole; DiOC6(3), 3,3′
dihexiloxalocarbocyanine iodide; H2DCFDA, 2′,7′-dichlorodihydrofluorescein diacetate; HE, hydroethidine; IB, immunoblotting; IC, intracellular; IF,
(immuno)fluorescence microscopy; IM, mitochondrial inner membrane; OM, mitochondrial outer membrane; MPT, mitochondrial permeability transition;
PI, propidium iodide; PS, phosphatidylserine; ROS, reactive oxygen species; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labeling; UV, ultraviolet
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Table 4
Spectrophotometry applied to cell death research
Method Advantages Drawbacks Notes
ELISA-based methods
  Caspase activation Based on standard laboratory
equipment
Requires cell lysis or the use of
cell-free fluids
Based on antibodies that
specifically
  assays Quantitative data on the
presence of active caspases
(e.g., plasma) recognize the active fragments of
Caspase activation may occur in
cell death-unrelated
Caspases
  Chromatin fragmentation Largely more sensitive than
agarose gel electrophoresis
Standardization is required to
obtain reliable results
Based on the quantification of
dissociated
  tests Detection of
cytoplasmicversus EC
nucleosomes allows
Antibodies in some commercial
kits do not fix
nucleosomes released from the
for the estimation of
apoptoticversus nonapoptotic
cell
nucleosomes from all human cell
types
chromatin of dying cells (in the
cytosol
death May require fractionation and/or in EC fluids)
  Cytokeratin 18 cleavage Provides a means to estimate
the proportion of apoptotic
Limited to cytokeratin 18-
expressing (epithelial) cells
Based on the detection in EC fluids
of
  and release assays versus nonapoptotic cell
death in vivo
Each sample requires two distinct
ELISA-based
caspase-cleaved versus full-length
assessments cytokeratin 18
  Expression of death Crude and/or impure samples
can be used without
Augmented expression of death
receptors and/or of
Used to detect the presence of
death
  receptors and/or ligands affecting binding selectivity their ligands may not necessarily
result in increased
receptors and/or of their ligands at
the
cell death surface of cells or within body
fluids
  Release of IC proteins Allows for the identification
of cytostatic versus cytotoxic
Released proteins decay due to
both enzymatic and
IC proteins in culture supernatants
and/or
  into EC fluids (e.g., NMP) effects nonenzymatic reactions that
normally occur in EC fluids
body fluids indicate plasma
membrane
No need for laborious sample
preprocessing
breakdown
  Release of IMS proteins High sensitivity (as compared
to IF and IB)
Subcellular fractionation required Based on the detection of IMS
proteins in
  from mitochondria Provides precise quantitative
data
Stringent need for analytical
standardization
distinct subcellular compartments
  (e.g., AIF, Cytc)
Others
  Large amplitude swelling Allows the study of MPTin
vitro, in mitochondria
purified
Dependent on the purity of the
mitochondrial
Mitochondria undergoing MPT
swell, and
from rodent liver or cell
cultures
suspension this leads to a decrease in
absorbance
Permits excluding the activity
of metabolic intermediates/
Purified mitochondria are stable
for a limited time frames
products Unsuitable for large-scale or high-
throughput
Basic laboratory equipment applications
  LDH release assays Relatively inexpensive (as
compared to ELISA-based
Cannot discriminate between
distinct subroutines of
Detects by colorimetric means the
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Method Advantages Drawbacks Notes
tests) cell death enzymatic activity of LDH
released by
Based on standard laboratory
equipment and rapid
LDH stability in supernatants and
body fluids as well as its
enzymatic activity can be affected
by several
dead cells (in culture supernatants
or
Appropriate for the first
rounds of high-throughput
studies
as its enzymatic activity can be
affected by several
body fluids)
  Tetrazolium salt Relatively inexpensive (as
compared to ELISA-based
Mitochondrial activity may be
shut down in cell
The conversion of a cell-permeant,
  conversion assays tests) death-unrelated settings (e.g.,
overconfluence)
colorless salt of tetrazolium by
  (e.g., MTT, MTS,
WST-1)
Based on standard laboratory
equipment and rapid
MTT is converted to cytotoxic,
water-insoluble
mitochondrial dehydrogenases is
MTS and WST-1 can be used
for real-time
formazan employed as an indicator of viable
cells
Appropriate for the first
rounds of high-throughput
studies
Require some optimization, since
conversion efficiency
differs in distinct cell lines
Abbreviations: AIF, apoptosis-inducing factor; Cyt c, cytochrome c; EC, extracellular; ELISA, enzyme-linked immunosorbent assay; IB, immunoblotting;
IC, intracellular; IF, (immuno)fluorescence microscopy; LDH, lactate dehydrogenase; MPT, mitochondrial permeability transition; MTS, 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide; NMP, nuclear matrix protein; WST-1, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-terazolio]-1,3-benzene disulfonate
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Table 5
Other techniques to detect cell death-related phenomena
Method Advantages Drawbacks Notes
Agarose gel electrophoresis Allows for the discrimination
between apoptotic versus
nonapoptotic instancesof cell
death
Requires DNA isolation
Inappropriate for large-scale
applications Detection often based
on carcinogenic dyes
Internucleosomal DNA
fragmentation results in
the so-called DNA ladder
Caspase Miniaturized Caspase activation may occur in cell
death-unrelated scenarios
Caspase activation is
detected by cell-permeant
fluorogenic
activation Allows for large-scale and
high-throughput applications
Fluorogenic caspase substrates can
bestored for limited time
substrates
assays Standard laboratory
equipment (multi-well
fluorescence reader)
Clonogenic Determine the long-term fate
of cells
Require proliferating cells Widely used in cancer
research to
assays Inexpensive and based on
standard laboratory
equipment
Cannot discriminate between cell
death and senescence Laborious and
time consuming
evaluate the long-term
effects of radio- and
chemotherapy
HPLC Very-high sensitivity (as
compared to IB, IF and
ELISA-based methods)
Rapid (as compared to IB)
Dedicated technological platform
Requires trained personnel Needs
subcellular fractionation Protocols
may demand for extensive
optimization
Applied to the detection
of Cyt c release
ImageStream Allows for the simultaneous
acquisition from each flowing
cell of both overall
fluorescence and of multiple
microphotographs
Expensive technological platform
Unsuitable to study rare events
Automation of the analytical
procedures may be problematical
Employed to discriminate
among live, apoptotic and
necrotic cells, as well as
to measure apoptotic
index
MS May provide a large amount
of experimental data (e.g.,
analysis of the entire
proteome released by
mitochondria undergoing
MMP)
Expensive technological platform
Requires qualified operators
Prolonged optimization of the
protocols may be necessary
Used to characterize cell
death-related changes in
the proteome of specific
subcellular
compartments
Compatible with quantitative
applications
Unsuitable for high-throughput
applications
NMR Allows for the identification
of MOMP, MPT and other
scenarios of cell death at a
molecular level
Only on purified components Highly
expensive instrument that requires
trained personnel
The NMR properties of
structured water within
mitochondria change in
distinct cell death-related
Identify more complex cell
death scenarios, as those
occurring in vivo
Inappropriate for routine
determinations
scenarios
Abbreviations: Cyt c, cytochrome c; ELISA, enzyme-linked immunosorbent assay; HPLC, high-pressure liquid chromatography; IB, immunoblotting;
IF,(immuno)fluorescence microscopy; MMP, mitochondrial membrane permeabilization; MOMP, mitochondrial outer membrane permeabilization; MPT,
mitochondrial permeability transition; MS, mass spectrometry; NMR, nuclear magnetic resonance
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